American Society of Hematology

Action Alerts

From time to time ASH will call on its members to reach out to Congress and state legislatures on issues of importance to hematologists and their patients. Below is a list of current issues of importance.

Federal Campaigns

Urge Your Elected Officials to Provide Dedicated Funding for SCD Data Collection
As the appropriations process continues in the House of Representatives and Senate for fiscal year (FY) 2020, ASH is working hard to expand key sickle cell disease (SCD) programs within the Centers for Disease Control and Prevention (CDC).

Tell Congress to Support NIH Funding for FY 2020
The Society needs the help of all its members to urge lawmakers to support the robust, sustained, and predictable funding increases for NIH that are currently proposed in the Labor-HHS spending bill. You can help spread this message by quickly sending an email to your legislators.

Urge Your Senators and Representative to Support the Cancer Drug Coverage Parity Act
Legislation has been reintroduced in the U.S. House of Representatives and U.S. Senate that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. The Cancer Drug Coverage Parity Act would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port administered, or injected anticancer medications.

State-Level Campaigns

Check back again for future updates on ASH’s State-Level Campaigns.

Write Your New Jersey Legislators to Support Patients' Access to Care
Legislation has been introduced in the New Jersey Legislature that would ensure that patients have access to the life-saving medication that is prescribed to them by their physicians. S. 1865 will place maximums on the out-of-pocket (OOP) costs that patients can be required to pay for each prescription medication, regardless of the disease. The legislation caps patient OOP costs for prescription medications within state regulated plans and would dramatically improve affordability for patients without significantly altering the existing insurance marketplace. This bill has already passed the New Jersey Assembly by a vote of 77-1 in March and now faces its first hearing in the Senate Commerce Committee on June 13.

back to top